Home > Boards > US OTC > Delisted >

Unigene Laboratories Inc (fka UGNEQ)

RSS Feed
Add Price Alert      Hide Sticky   Hide Intro
Search This Board: 
Last Post: 7/1/2019 9:55:07 AM - Followers: 11 - Board type: Free - Posts Today: 0

About Unigene Our Mission To leverage the broad utility of our patented manufacturing and delivery technologies to create a new generation of safe and effective peptide pharmaceuticals that can provide a more natural approach to the prevention and treatment of disease. Our Purpose To enable our partners and clients to develop peptide and protein drugs for the treatment of a variety of chronic diseases, thereby enhancing the health and well-being 3 Month Chart 6 Month Our History Rollover an Orb on the DNA strand to see one of our Corporate Milestones Founded in 1980, Unigene is a publicly traded biopharmaceutical company with corporate offices, an R&D facility and a state-of-the-art recombinant manufacturing facility in New Jersey. Our broad experience in molecular biology, protein chemistry, immunology and formulation development combined with our entrepreneurial spirit and innovation have led to the development of proprietary technologies, protected by a strong patent portfolio, enabling the commercialization of peptide drugs. Our technologies and products are licensed and utilized by some of the world’s leading pharmaceutical companies and we have collaborations with world-renowned universities to develop peptides and technologies. Why Unigene Unigene is unique among biopharmaceutical companies in that we offer a combination of manufacturing and delivery technologies that enable commercialization of peptide-based pharmaceuticals. Unigene’s extensive product development experience and capabilities will expedite time to market for our partner’s products. Product Pipeline Peptide Product Development Stage Availability/ Partner Preclinical P1 P2 P3 Regulatory Review Approval sCT nasal U.S. (Fortical®) Upsher Smith sCT injectable (Forcaltonin®) Worldwide** sCT nasal Outside US** sCT oral Worldwide PTH analogs oral GSK GLP-1 analogs oral Worldwide Leuprolide oral Worldwide Desmopressin Worldwide SDBG* Worldwide CGRP Worldwide *Site Directed Bone Growth **Except Greece and China MAJOR PRESS RELEASES Feb. 7,2007 Unigene Achieves $5.5 Million Milestone in Calcitonin Collaboration for Phase III Initiation 8:17a ET February 27, 2007 (Business Wire) The initiation of a Phase III clinical study for osteoporosis by Nordic Bioscience, the development partner of Novartis Pharma AG, with oral calcitonin has triggered a $5.5 million milestone to be paid by Novartis to Unigene Laboratories, Inc. (OTCBB: UGNE). Salmon calcitonin, the active pharmaceutical ingredient in Novartis' oral product, was produced using Unigene's patented manufacturing process, which was licensed to Novartis in 2004. In 2005, the technology was transferred successfully to Sandoz, an affiliate of Novartis, who produced multiple kilograms of calcitonin at a scale that represents a ten-fold increase above Unigene's current production capacity. Under the terms of that agreement, Unigene is eligible to receive up to $18.7 million in payments before royalties. Upon receipt of this milestone payment, Unigene will have received $13.7 million of that total. "We are pleased that a pivotal study has started with an oral product made with our calcitonin manufacturing technology," commented Dr. Ronald S. Levy, Executive Vice President of Unigene. "This action confirms Novartis' intention to utilize Unigene's technology to commercialize the product. We believe that this study, combined with Novartis' planned study for oral calcitonin in osteoarthritis, will serve to highlight the significant potential market opportunities for calcitonin-based products in the future." ________ Jan. 4,2008 Shijiazhuang Pharma and Unigene to set up JV to produce osteoporosisdrug Shanghai. January 4. INTERFAX-CHINA - Shijiazhuang Pharmaceutical Group Co. Ltd. and U.S.-based Unigene Laboratories have recently signed an agreement to set up a joint venture that would produce an osteoporosis drug, a company official told Interfax yesterday. "The two sides will both inject $15 million to set up the joint venture, which will produce calcitonin salmon," a Shijiazhuang Pharma manager overseeing the project, surnamed Wang, said. An effective osteoporosis treatment, calcitonin salmon is currently produced through chemical synthesis, which, according to Wang, is an inefficient production method. Unigene produces the drug using genetic fermentation technology, which is more cost-effective than chemical synthesis. "The joint venture will be competitive when it is up against well- established domestic companies, in terms of technology and production costs of calcitonin salmon," Wang said. The joint venture is expected to produce 70 million calcitonin salmon injections and 4 million calcitonin salmon nasal sprays per year, with annual sales expected to reach RMB 708 million ($97.25 million), including projected exports of $50 million. Production of the drug is expected to start before the end of this year, Wang said. The joint venture also plans to establish a biotechnology development platform to develop and commercialize other biotech drugs. -KZ About Unigene Unigene Laboratories, Inc. is a biopharmaceutical company focusing on the oral and nasal delivery of large-market peptide drugs. Due to the size of the worldwide osteoporosis market, Unigene is targeting its initial efforts on developing calcitonin and PTH-based therapies. Fortical(R), Unigene's nasal calcitonin product for the treatment of postmenopausal osteoporosis, received FDA approval and was launched in August 2005. Unigene has licensed the U.S. rights for Fortical to Upsher-Smith Laboratories, worldwide rights for its oral PTH technology to GlaxoSmithKline and worldwide rights for its calcitonin manufacturing technology to Novartis. The Company is also manufacturing a second peptide for Novartis. Unigene's patented oral delivery technology has successfully delivered, in preclinical and/or clinical trials, various peptides including calcitonin, PTH and insulin. Unigene's patented manufacturing technology is designed to cost-effectively produce peptides in quantities sufficient to support their worldwide commercialization as oral or nasal therapeutics. For more information about Unigene, call (973) 882-0860 or visit www.unigene.com. For information about Fortical, visit www.fortical.com. Safe Harbor statements under the Private Securities Litigation Reform Act of 1995: This press release contains forward-looking statements as defined in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such forward-looking statements are based upon Unigene Laboratories, Inc.'s management's current expectations, estimates, beliefs, assumptions, and projections about Unigene's business and industry. Words such as "anticipates," "expects," "intends," "plans," "predicts," "believes," "seeks," "estimates," "may," "will," "should," "would," "potential," "continue," and variations of these words (or negatives of these words) or similar expressions, are intended to identify forward-looking statements. In addition, any statements that refer to expectations, projections, or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. These forward-looking statements are not guarantees of future performance and are subject to certain risks, uncertainties, and assumptions that are difficult to predict. Therefore, our actual results could differ materially and adversely from those expressed in any forward-looking statements as a result of various risk factors. These risks and uncertainties include the risks associated with the effect of changing economic conditions, trends in the products markets, variations in Unigene's cash flow, market acceptance risks, technical development risks and other risk factors detailed in Unigene's Securities and Exchange Commission filings. SOURCE: Unigene Laboratories, Inc. Investor Contact: The Investor Relations Group Daniel Berg/Dian Griesel, Ph.D., 212-825-3210 or Media: Janet Vasquez, 212-825-3210 http://www.unigene.com/
#513   UGNEQ registration revoked: Renee 07/01/19 09:55:07 AM
#512   UGNEQ SEC Suspension for severely delinquent Financials/Filings: Renee 09/14/18 09:34:08 AM
#511   Anyone have thoughts on the out of the FarmerMatt 03/20/18 04:35:12 PM
#510   BOOM! rising 10/24/17 07:43:41 PM
#509   UGNEQ, trending up again here the past couple days. Garyst 12/29/16 10:23:50 PM
#508   UGNEQ CLIMBING...GOING TO EXPLODE...NEXT SARAQ...Q WILL SAY BYE-BYE.. halbroke1 12/29/16 01:31:13 PM
#507   UGNEQ insanely thin to the upside. Hit 006 Garyst 12/23/16 03:04:41 PM
#506   UGNEQ >>>> GOING TO EXPLODE $$$$ THE NEXT SARAQ.... halbroke1 12/23/16 12:26:17 PM
#505   Since on one has intelligently responded to my ElSid18 12/03/16 05:55:09 PM
#504   UGNEQ 150% today. Garyst 12/01/16 08:40:17 PM
#503   UGNEQ >>>> EXPLOSION COMING...LOAD THE CHEAPIES $$$$$$$ halbroke1 11/24/16 05:57:55 PM
#502   Between Tarsa, Enteris, UGNEQ losing its q, does ElSid18 11/23/16 08:13:26 AM
#501   Nice bounce today and some large buys EOD Garyst 11/22/16 09:18:44 PM
#500   UGNEQ WILL BE A BEAST WHEN THE Q halbroke1 11/22/16 07:12:37 PM
#499   Still holding 0011 42% Garyst 11/22/16 03:16:13 PM
#498   SOMETHING BIG WILL BE ANNOUNCED IT UGNEQ.... I halbroke1 11/22/16 03:12:57 PM
#497   100% 0016, nothing there to 01. Has bounced Garyst 11/22/16 02:03:28 PM
#496   Chinese need to smoke some WEED too makinezmoney 11/21/16 02:36:13 PM
#495   UGNEQ 66% 001, 0017 on ask with 001 bidding Garyst 11/21/16 02:32:33 PM
#494   Agree. Just got on a bit ago and Garyst 11/18/16 11:25:28 AM
#493   UGNEQ....THIS GEM $$$$$ WILL QUIETLY EXPLODE BIG... halbroke1 11/18/16 11:21:40 AM
#492   Still very thin on L2 but also very quiet. Garyst 11/17/16 08:59:56 PM
#491   Sure is a quiet day. Garyst 11/15/16 03:44:28 PM
#490   UGNEQ 001 165k to 004 Garyst 11/15/16 02:27:51 PM
#489   No sellers today, one good sign. Garyst 11/15/16 01:28:07 PM
#488   UGNEQ MEGA-MERGER WITH ENTERIS WILL BE HUGE $$$$$$...GET halbroke1 11/15/16 12:54:48 PM
#487   Yup, holding tight. Just putting some posts up Garyst 11/15/16 11:18:31 AM
#486   UGNEQ...>>>> NEXT SARAQ....SOMETHING BIG COMING...WHEN Q FALLS, IT halbroke1 11/15/16 11:16:13 AM
#485   Just started getting some action last week. Ran Garyst 11/15/16 11:05:18 AM
#484   Old news UGNEQ m0n 11/15/16 09:09:02 AM
#483   what's going in here? Natural Trader 11/15/16 08:34:05 AM
#482   3 Enteris Managers from Unigene Labs makinezmoney 11/15/16 12:26:50 AM
#481   I think so. 68% today top, 430% Fri Garyst 11/14/16 08:52:37 PM
#480   Nice. Garyst 11/14/16 08:51:58 PM
#479   Go UGNEQ >>> Congrats. We are on Ticker MVIR 11/14/16 07:09:59 PM
#478   looking good here C-Money365 11/14/16 06:59:54 PM
#477   Setting up. UGNEQ is gonna go. Garyst 11/14/16 04:05:03 PM
#476   1000 share $1 trade just knocked it back Garyst 11/14/16 03:23:51 PM
#475   UGNEQ..GOING TO BLOW-UP...BANKRUPTSY MIGHT BE FINISHED... $$$$$$...COMING...ANOT halbroke1 11/14/16 03:20:46 PM
#474   0015 bidding now. Pretty thin to 005 Garyst 11/14/16 03:05:28 PM
#473   .0021 on the ASK now glens0 11/14/16 03:01:35 PM
#472   Nice 300k hit on the ask there. Garyst 11/14/16 02:34:33 PM
#471   UGNEQ 68% 0015, under 800k to 01 Garyst 11/14/16 01:59:37 PM
#470   Agree and it is thin and easy to Garyst 11/14/16 01:35:54 PM
#469   LOOKS LIKE UGNEQ READY TO BUST TO THE halbroke1 11/14/16 01:21:51 PM
#468   UGNEQ moves so easy! 0019 up m0n 11/14/16 01:20:32 PM
#467   Agree. more volume would do us well but Garyst 11/14/16 11:41:36 AM
#466   We need more interest glens0 11/14/16 11:25:46 AM
#465   UGNEQ 23% 0011, 430% Fri off LOD, 900% Garyst 11/14/16 10:42:41 AM
#464   CDEL Holding this down IMO UGNEQ m0n 11/14/16 10:00:00 AM
Consent Preferences